Form 4: BioLargo Director Receives New Equity Compensation

BioLargo director Dennis E. Marshall was granted new stock options as compensation for services and to replace an expired option.

Summary

• Dennis E. Marshall, a Director of BioLargo, Inc. (BLGO), reported changes in his beneficial ownership of derivative securities.
• Marshall was granted an option to purchase 122,084 shares of common stock at an exercise price of $0.1843, exercisable from December 31, 2025, and expiring on December 31, 2035.
• This option replaces a previously expired option to purchase 45,000 shares, which had been issued to compensate Marshall for $22,500 in services.
• A second option was granted to purchase 101,736 shares of common stock at an exercise price of $0.17, also exercisable from December 31, 2025, and expiring on December 31, 2035.
• This second option serves as payment for $18,750 in fees due to Marshall for his services on the board of directors for the most recently completed quarterly period.
• The grants were made pursuant to a plan adopted by the Issuer's Compensation Committee and the Issuer's 2024 Equity Incentive Plan.
• Following these transactions, Marshall beneficially owns 5,246,381 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive. While a previous option expired unexercised, the company has addressed director compensation with new grants, maintaining alignment of interests. This is a routine compensation event.

Positives

• Director Dennis E. Marshall received new stock options, aligning his interests with shareholders.
• The company is compensating its director for services rendered, indicating ongoing board engagement.
• The replacement of an expired option ensures continued compensation for past services valued at $22,500.

Negatives

• A previous option for 45,000 shares expired unexercised due to a discrepancy between the original exercise price and the Issuer's current stock price, suggesting potential past stock underperformance or an initially high strike price.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the expiration dates of the granted options.

Management Comments

• The option to purchase 122,084 shares was granted to compensate the Reporting Person for $22,500 in services to the Issuer and to replace an option for 45,000 shares that had recently expired unexercised due to a discrepancy between the original exercise price and the Issuer's current stock price, pursuant to a plan adopted by the Issuer's Compensation Committee.
• The option to purchase 101,736 shares was issued to the Reporting Person as payment for $18,750 in fees due for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

Industry Context

This Form 4 filing reflects routine director compensation practices within publicly traded companies, where equity incentives are commonly used to align management and director interests with long-term shareholder value. The specific details of option grants and their terms are typical for such compensation structures.

Comparison to Industry Standards

• The use of stock options as compensation for directors is a standard practice across various industries, including the biotechnology and environmental technology sectors where BioLargo operates.
• The structure of replacing expired options and granting new ones for ongoing services is consistent with corporate governance best practices aimed at retaining experienced board members and incentivizing performance.
• The exercise prices of $0.1843 and $0.17 are specific to BioLargo's stock valuation at the time of grant and would need comparison to peer companies' director compensation packages to assess competitiveness, which is not detailed in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: The granting of options to a director aligns the director's financial interests with the long-term performance of the company's stock, potentially incentivizing decisions that benefit shareholders.
• Employees: No direct impact mentioned, but the existence of an Equity Incentive Plan suggests a broader framework for equity compensation that could extend to other key personnel.

Key Dates

Keywords

BioLargo, BLGO, SEC Form 4, stock options, director compensation, equity incentive plan, beneficial ownership, derivative securities